Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Literature DB >> 28242618

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Sébastien Le Burel¹, Stéphane Champiat^2,3, Emilie Routier⁴, Sandrine Aspeslagh², Laurence Albiges⁵, Tali-Anne Szwebel⁶, Jean-Marie Michot², Pascale Chretien⁷, Xavier Mariette^8,9,10,11, Anne-Laure Voisin¹², Olivier Lambotte^1,9,10,11.

Abstract

Entities: Disease Gene

Keywords: Autoantibodies; Autoimmune Diseases; Autoimmunity; Sjøgren's Syndrome; Treatment

Mesh：

Substances：

Year: 2017 PMID： 28242618 DOI： 10.1136/annrheumdis-2016-210820

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

Keyword Cloud
Cited

× No keyword cloud information.

18 in total

1. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.

Authors: Sanjay S Shete; Maria E Suarez-Almazor; Noha Abdel-Wahab; Adi Diab; Robert K Yu; Andrew Futreal; Lindsey A Criswell; Jean H Tayar; Ramona Dadu; Vickie Shannon
Journal: Cancer Immunol Immunother Date: 2021-01-07 Impact factor: 6.968

Review 2. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review.

Authors: Teresa M Crout; Day S Lennep; Shweta Kishore; Vikas Majithia
Journal: Curr Rheumatol Rep Date: 2019-05-21 Impact factor: 4.592

3. Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.

Authors: Ariadna Ortiz Brugués; Vincent Sibaud; Beatrice Herbault-Barrés; Sarah Betrian; Iphigenie Korakis; Caroline De Bataille; Carlos Gomez-Roca; Joel Epstein; Emmanuelle Vigarios
Journal: Oncologist Date: 2019-11-06

4. Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.

Authors: Pradnya D Patil; Anthony P Fernandez; Vamsidhar Velcheti; Ahmad Tarhini; Pauline Funchain; Brian Rini; Mohamad Khasawneh; Nathan A Pennell
Journal: Oncologist Date: 2018-10-24

10. MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma.

Authors: Renhong Huang; Xiaowei Zhang; Zhijun Min; Abdelbari Sophia Shadia; Shun'e Yang; Xiaojian Liu
Journal: Exp Ther Med Date: 2018-09-03 Impact factor: 2.447

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

1. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors.

Review 2. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review.

3. Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending.

4. Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.

5. Acral vascular syndrome during an immune checkpoint inhibitor.

6. Nivolumab-induced sialadenitis.

Review 7. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors.

Review 8. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.

9. A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.

10. MGCD0103 induces apoptosis and simultaneously increases the expression of NF-κB and PD-L1 in classical Hodgkin's lymphoma.